CS276204B6 - Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 - Google Patents
Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 Download PDFInfo
- Publication number
- CS276204B6 CS276204B6 CS905122A CS512290A CS276204B6 CS 276204 B6 CS276204 B6 CS 276204B6 CS 905122 A CS905122 A CS 905122A CS 512290 A CS512290 A CS 512290A CS 276204 B6 CS276204 B6 CS 276204B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- interferon alpha
- human interferon
- ifna1
- monoclonal antibody
- mouse hybridoma
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 24
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 24
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 18
- 230000027455 binding Effects 0.000 title description 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 4
- 102000018358 immunoglobulin Human genes 0.000 abstract description 4
- 238000004140 cleaning Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000051101 human IFNA1 Human genes 0.000 description 2
- 108700028467 human IFNA1 Proteins 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Účelom riešenia je příprava novej homogénnej protilátky, ktorá sa viaže s l’udským interferonom alfa 1 a neviaže sa s iný mi subtypmi ludského interferonu alfa. Uvedeného účelu sa dosiahne použitím nového myšieho hybridómu IFNA1-118, produkujúceho monoklonálnu protilátku imunoglobulínovej podtriedy G1 voči rekombinantnému ludskému interferonu alfa 1. Myší hybridóm IFNA1-118 má použitie v imunodiagnostike a při čistění ludského interferonu alfa 1.The purpose of the solution is to prepare a new homogeneous antibody that binds to human interferon alpha 1 and does not bind to another interferon alpha subtypes. the purpose is achieved by using a new one mouse hybridoma IFNA1-118 producing immunoglobulin monoclonal antibody G1 subclass against recombinant human interferon alpha 1. Mouse hybridoma IFNA1-118 has use in immunodiagnostics and in cleaning human interferon alpha 1.
Description
Vynález sa týká nového myšieho hybridómu IFNA1-118 produkujúceho monoklonálnu protilátku, ktorá sa viaže s 1’udským interferonom alfa 1,The invention relates to a novel monoclonal antibody producing mouse IFNA1-118 hybridoma that binds to human alpha 1 interferon,
Protilátky voči 1’udskému interferónu alfa 1 sa pripravujú vo formě antisér alebo monoklonálnych protilátok. Antiséra sa získavajú imunizáciou pokusných zvierat purifikovaným antigénom (1’udským interferonom alfa 1). Takto připravené protilátky sú rieštandardné a sú vždy zmesou protilátok s vazobnými a s neutralizačnými schopnosťami voči fudskému interferonu alfa 1. Antiséra vykazujú aj krížovú reaktivitu s příbuznými subtypmi fudského interferonu alfa. Přípravu homogénnych protilátok s výlučné vazobnou aktivitou voči fudskému interferónu alfa 1 umožňuje iba hybridómová technika přípravy monoklonálnych protilátok.Antibodies to human interferon alpha 1 are prepared in the form of antisera or monoclonal antibodies. Antisera are obtained by immunizing test animals with purified antigen (1 ' human interferon alpha 1). The antibodies thus prepared are standard and are always a mixture of antibodies with binding and neutralizing properties to human interferon alpha 1. Antisera also show cross-reactivity with related subtypes of human interferon alpha. Only hybridoma techniques for the production of monoclonal antibodies allow the production of homogeneous antibodies with exclusive binding activity to human interferon alpha 1.
Takéto monoklonálne protilátky umožňujú důkaz přítomnosti fudského interferónu alfa 1 v roznych biologických materiáloch pomocou citlivých imunochemických stanovení. Hybridómy sa získavajú známým spůsobom opísaným v literatúre /G. Kóhler, C. Milstein: Nátuře, 256 (1975)/. Hybridóm IFNA1-118 nebol doteraz připravený.Such monoclonal antibodies allow the detection of the presence of human interferon alpha 1 in a variety of biological materials by sensitive immunochemical assays. Hybridomas are obtained by a known method described in the literature / G. Kohler, C. Milstein: Nature, 256 (1975) /. The IFNA1-118 hybridoma has not been prepared yet.
Nevýhody konvenčně připravených antisér voči fudskému interferónu alfa 1 v podstatnej miere odstraňuje vynález, ktorého podstatou je myší hybridóm IFNA1-118, produkujúci monoklonálnu protilátku imunoglobulínovej podtriedy Gl, ktorá má schopnost’ Specificky reagovať s rekombinantným 1’udským interferonom alfa 1. Hybridóm IFNA1-118 je uložený vo Virologickom ústave SAV, Dúbravská cesta 9, 842 46 Bratislava.The disadvantages of conventionally prepared antisera against human interferon alpha 1 are substantially eliminated by the invention, which is a murine hybridoma IFNA1-118, producing a monoclonal antibody of immunoglobulin subclass G1, which has the ability to specifically react with recombinant 1'human interferon alpha 1. Hybridoma IFNA1-118 is deposited in the Institute of Virology of SAS, Dubravska cesta 9, 842 46 Bratislava.
Výhodou hybridómu IFNA1-118 je, že produkuje homogénnu protilátku, ktorá je schopná Specificky reagovať iba s 1’udským interferonom alfa 1 a nerozoznáva iné subtypy fudského interferónu alfa. Po rozmražení buňky hybridómu IFNA1-118 pokračujú v produkcii protilátky i bez Salšej imunizácie 1’udským interferonom alfa 1.An advantage of the IFNA1-118 hybridoma is that it produces a homogeneous antibody that is capable of specifically reacting only with 1 ' human interferon alpha 1 and does not recognize other subtypes of human interferon alpha. After thawing, IFNA1-118 hybridoma cells continue to produce antibody without Saler immunization with human interferon alpha 1.
Příklad 1Example 1
Hybridómy sa získajú fúziou myších myelómových buniek NSO a buniek získaných zo sleziny myší kmeňa BALB/c imunizovaných rekombinantným 1’udským interferonom alfa 1 (ErnstBoehringer-Institut fór Arzneimittelforschung, Viedeň). Po fúzii bol vybratý hybridóm IFNA1-118, ktorý ' produkuje monoklonálnu protilátku imunoglobulínovej podtriedy Gl, selektívne sa viažúcu s 1’udským interferonom alfa 1. Hybridóm IFNA1-118 sa pestuje in vitro v kultivačných médiach alebo in vivo v peritoneálnej dutině myši kmeňa BALB/c. Buňky sa zmrazujú a uchovávajú v kvapalnom dusíku a po rozmražení pokračujú v produkcii protilátky bez Salšej imunizácie l’udským interferonom alfa 1. Buňky hybridómu IFNA1-118 rastů in vitro ako suspenzná kultúra a produkujú do kultivačného média přibližné 1 ug/ml špecifickej protilátky. Kultivačným médiom je Dulbeccova modifikácia Eagleovho minimálneho esenciálneho média /R. Dulbecco,. G. Freeman: Virology B, 396 (1959)/. Toto médium je pre kultiváciu hybridómov doplněné inaktivovaným koňským sérom (ELÁN CLONĚ). Za účelom získania váčšieho množstva monoklonálnej protilátky proti fudskému interferónu alfa 1 sa buňky IFNA1-118 aplikovali v množstve 5.10^ do peritoneálnej dutiny myši BALB/c. Myš sa desať dní před touto aplikáciou premedikuje parafínovým olejom (0,5 ml intraperitoneálne na myš). Po 10 až 15 dňoch od injekcie buniek IFNA1-118 bola myši odobratá ascitická tekutina, ktorá obsahuje požadovanú monoklonálnu protilátku v koncentrácii přibližné 1 mg/ml.Hybridomas are obtained by fusing mouse NSO myeloma cells and cells obtained from the spleen of BALB / c mice immunized with recombinant human alpha 1 interferon (ErnstBoehringer-Institut Forum Arzneimittelforschung, Vienna). Following the fusion, the IFNA1-118 hybridoma, which produces a monoclonal antibody of immunoglobulin subclass G1, selectively binding to human interferon alpha 1, was selected. The IFNA1-118 hybridoma was grown in vitro in culture media or in vivo in the peritoneal cavity of BALB / mouse mice. C. Cells are frozen and stored in liquid nitrogen and, after thawing, continue to produce the antibody without saler immunization with human interferon alpha 1. In vitro IFNA1-118 hybridoma cells as suspension culture and produce approximately 1 µg / ml specific antibody in culture medium. The culture medium is Dulbecco's modification of Eagle's Minimum Essential Medium / R. Dulbecco ,. G. Freeman: Virology B, 396 (1959)]. This medium is supplemented with inactivated horse serum (ELAN CLONE) for hybridoma culture. In order to obtain a greater amount of monoclonal antibody against human interferon alpha 1, IFNA1-118 cells were administered in an amount of 5 x 10 6 to the peritoneal cavity of BALB / c mice. The mice are pre-treated with paraffin oil (0.5 ml intraperitoneally per mouse) ten days prior to this application. 10 to 15 days after injection of IFNA1-118 cells, ascites fluid containing the desired monoclonal antibody at a concentration of approximately 1 mg / ml was collected from the mice.
Myší hybridóm IFNA1-11B sa používá ako zdroj homogénnej protilátky imunoglobulínovej podtriedy Gl, ktorá selektívne viaže ale neneutralizuje 1’udský interferón alfa 1, pričom nereaguje s inými subtypmi fudského interferónu alfa. Připravená protilátka sa používá na detekciu fudského interferónu alfa 1 v imunochemických testoch ELISA, RIA, imunoblot a v imunohistochémii. Protilátka je vhodná aj na imunoafinitnú purifikáciu fudského interferonu alfa 1.The murine hybridoma IFNA1-11B is used as a source of a homogeneous antibody of immunoglobulin subclass G1, which selectively binds but does not neutralize human interferon alpha 1 and does not react with other human interferon alpha subtypes. The prepared antibody is used to detect human interferon alpha 1 in immunoassay ELISA, RIA, immunoblot and immunohistochemistry. The antibody is also suitable for immunoaffinity purification of human interferon alpha 1.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS905122A CS276204B6 (en) | 1990-10-22 | 1990-10-22 | Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS905122A CS276204B6 (en) | 1990-10-22 | 1990-10-22 | Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS512290A3 CS512290A3 (en) | 1992-04-15 |
| CS276204B6 true CS276204B6 (en) | 1992-04-15 |
Family
ID=5395490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS905122A CS276204B6 (en) | 1990-10-22 | 1990-10-22 | Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS276204B6 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
-
1990
- 1990-10-22 CS CS905122A patent/CS276204B6/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US7582445B2 (en) | 2001-02-22 | 2009-09-01 | Genentech, Inc. | Anti-interferon-α antibodies |
| US7910707B2 (en) | 2001-02-22 | 2011-03-22 | Genentech, Inc. | Anti-interferon-α antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| CS512290A3 (en) | 1992-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105579471B (en) | Antibodies that bind human programmed death ligand 1(PD-L1) | |
| US5047507A (en) | Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen | |
| AU2008243049B2 (en) | Novel compounds | |
| KR101335059B1 (en) | Anti-hepcidin antibodies and uses thereof | |
| JP5631733B2 (en) | Anti-EpCAM antibodies and uses thereof | |
| Zola | Monoclonal antibodies: the second generation | |
| HRP20040147A2 (en) | Antagonistic anti-htnfsf13b human antibodies | |
| CA2456648A1 (en) | Human antibodies specific for interleukin 15 (il-15) | |
| WO2022105914A1 (en) | Antibody binding to cd70 and application thereof | |
| US11661452B2 (en) | Anti-lag-3 antibody polypeptide | |
| RU2018135550A (en) | Binding ILT7 MOLECULES AND METHODS OF APPLICATION | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| Lewis et al. | Conformation-specific monoclonal antibodies directed against the calcium-stabilized structure of human prothrombin | |
| AU2003219954A1 (en) | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF | |
| CN107922939B (en) | Infectious monoclonal antibodies that neutralize all species of Ebola virus | |
| US20210115138A1 (en) | Novel bispecific pd-1/lag-3 antibody molecules | |
| CS276204B6 (en) | Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1 | |
| CS276203B6 (en) | Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2 | |
| Nagatani et al. | Production and characterization of monoclonal antibodies to rye (Secale cereale) phytochrome | |
| Pure et al. | Properties of a second epitope of the murine Fc receptor for aggregated IgG. | |
| CS276567B6 (en) | Murine hybridoma ifna2-n7 producing a monoclonal antibody | |
| WO2019109974A1 (en) | Anti-pd-l1 antibody and antigen-binding fragment thereof | |
| CS277142B6 (en) | Murine hybridoma ifna1-48 producing a monoclonal antibody | |
| Campbell et al. | Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies. | |
| ICHIMORI et al. | Establishment of hybridomas secreting monoclonal antibodies against Cε2 and Cε4 domains of human IgE |